Featured

CARM1 inactivation in cDC1s completes the antitumor trifecta

Coactivator-associated arginine methyltransferase (CARM1) is an epigenetic enzyme that controls transcription by methylating arginine residues of chromatin-associated proteins. In previous research, deletion or inhibition of CARM1 in tumor cells...

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth

Olea and Beede et al. identified Bacteroides rodentium and Bacteroides uniformis (found in mice and humans, respectively) as gut microbes that induced antitumor immunity and inhibited tumor growth in ...

In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum

Wang et al. engineered an “all-in-one” cancer cell-derived vaccine (UniCVac) by co-expressing CIITA, NLRC5, CD80, and IL-2 in tumor cells to mimic professional APCs with both HLA-I and HLA-II antigen ...

The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes

Kim et al. showed that anti-CTLA-4 efficacy in orthotopic murine glioblastoma (GBM) models was abolished by B cell deficiency and tdLN removal. In WT mice, anti-CTLA-4 increased B cell numbers and GC ...

mRNA lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antitumor activity

Zeng, Xu, and Wang et al. developed an optimized cancer vaccine platform comprising a novel LNP co-encapsulating tumor antigen mRNA and two STING agonists. In primary BM-DCs, vaccination synergistical...

See all for this week

Previous Digests

Turning up the heat: iSBRT and immunotherapy induce immune reprogramming in cold breast tumors in the clinic

July 15, 2026

The tumor immune microenvironment (TIME) of ER+HER2- high-risk early breast cancer is generally immune-cold, which limits immune checkpoint blockade (ICB) responses. Since radiotherapy may modulate the immune response, it may increase ICB efficacy. However, radiotherapy may also activate the...

Tregs versus Tconv: a battle over metastasis in PDAC

July 8, 2026

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and difficult-to-treat-tumor type with complex immune dynamics and multiple immune evasion mechanisms at different stages of disease. In work recently published in Science Immunology, Schmiechen et al. unraveled the roles of IFNγ-inducible...

Exhausted, yet effective: Eomes drives Th-mediated antitumor responses

July 1, 2026

While accumulating evidence suggests an important role for CD4+ T cells in antitumor immunity, the specific subpopulations responsible remain to be defined. Agesta, Ferrand, et al. investigated the function of the transcription factor Eomes in CD4+ T cell antitumor...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials